AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04178512
Drug: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
Trial: NCT01658956
Drug: GCSF administration on days 8 and 12 after chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00871351
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
Trial: NCT01486758
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
Trial: NCT01486758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01432522
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray
Trial: NCT01003171
Drug: MCS-2 soft-gel capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MCS-2 30 mg/day
Trial: NCT01175772
Drug: Cytophosphan, Celecoxib, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly
Trial: NCT00468130
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Trial: NCT02471859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at various doses, depending on the cohort and treatment period
Trial: NCT00436956
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral daily for 28 days
Trial: NCT04105972
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet for oral administration.
Trial: NCT04105972
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Trial: NCT01732146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455999
Drug: SYL1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYL1001 eye drops dose C administration for 10 consecutive days
Trial: NCT02455999
Drug: SYL1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYL1001 eye drops dose D administration for 10 consecutive days
Trial: NCT02455999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops administration for 10 consecutive days
Trial: NCT00238992
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01095133
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
Trial: NCT01095133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
Trial: NCT00878553
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet at bedtime
Trial: NCT04482192
Drug: Systemic analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
Trial: NCT04711486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo without any exipients.
Trial: NCT04706793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Trial: NCT00204269
Drug: Testosterone Gel Wolff
RxNorm normalized name: testosterone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01551069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT04063046
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
Trial: NCT00510146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, oral, once daily at bedtime, 6 weeks
Trial: NCT00066846
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00066846
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04181489
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 d1
Trial: NCT04181489
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 d1
Trial: NCT04181489
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60mg/m2 d1-5
Trial: NCT00947141
Drug: Stop treatment when 2 levels CMV PCR <3,000 copies / ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Trial: NCT00336336
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg die per os
Trial: NCT00336336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram c. per os
Trial: NCT00336336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg c. per os
Trial: NCT03260803
Drug: Oligopin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligopin ,150 mg ,once daily, 12 week
Trial: NCT03260803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,150 mg ,once daily, 12 week
Trial: NCT00715689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00715689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00715689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00715689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT01711398
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750451
Drug: low molecular weight heparin (enoxaparine sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
Trial: NCT00750451
Drug: crinone 8% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine luteal phase support with progesterone gel
Trial: NCT01020214
Drug: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01020214
Drug: Benicar HCT® Tablets 40 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03661996
Drug: CNTX-4975-05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
Trial: NCT03661996
Drug: Lidocaine without epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL lidocaine intra-articular injection
Trial: NCT01057030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 14 days
Trial: NCT03845023
Drug: AD036 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD036 Dose 1 oral capsule administered before sleep
Trial: NCT03845023
Drug: AD036 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD036 Dose 2 oral capsule administered before sleep
Trial: NCT03845023
Drug: AD036 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD036 Dose 3 oral capsule administered before sleep
Trial: NCT03845023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule administered before sleep
Trial: NCT01748123
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
Trial: NCT01182207
Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/0.02 mg Tablets
Trial: NCT04319614
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of saline will be administered in the beginning of the procedure.
Trial: NCT02918292
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
Trial: NCT04459221
Drug: Gardasil 9, 9-Valent Intramuscular Suspension
RxNorm normalized name: Gardasil 9, 9-valent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: access to HPV vaccination near the college in a health bus
Trial: NCT00352378
Drug: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
Trial: NCT03269747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Placebo tablets in the morning
Trial: NCT02020499
Drug: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
Trial: NCT02161406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of Placebo
Trial: NCT02450890
Drug: ORADUR® First, then Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
Trial: NCT01656395
Drug: MK-1029
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
Trial: NCT01656395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parts I-II: Participants will receive Placebo tablets QD
Trial: NCT04166604
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery
Trial: NCT03623932
Drug: immunosuppressor/TNFalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Treatment : immunosuppressor/TNFalpha as in standard practice
Trial: NCT01983462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03991988
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will take a matched placebo pill daily
Trial: NCT00671619
Drug: ESBA105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT04541732
Drug: Muscle Relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium : 0.5mg/Kg.
Trial: NCT04541732
Drug: Maintenance of general anaesthesia
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Trial: NCT00684203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
Trial: NCT01939561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is tablets identically with the Lamotrigine tablets.
Trial: NCT00399867
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02989571
Drug: Intravenous normal saline administered at 250ml/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline administered at 250ml/hr
Trial: NCT02989571
Drug: Intravenous normal saline administered at 125ml/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline administered at 125ml/hr
Trial: NCT02345044
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02345044
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02466243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE.
Trial: NCT00477464
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/m\^2 twice daily (14 days out of 21 days)
Trial: NCT03647384
Drug: Gulingji capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
Trial: NCT03647384
Drug: Ginko Biloba Extract tablet
RxNorm normalized name: Ginko biloba leaf oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
Trial: NCT01917006
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into specified muscle per protocol on Day 1.
Trial: NCT00624013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg up to 100 mg daily for 6 months
Trial: NCT00661544
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
Trial: NCT02219685
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT02219685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00226993
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03643497
Drug: anti-infective drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
Trial: NCT02217488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00742820
Drug: Calcium Acetate Oral Solution 667 mg per 5 mL
RxNorm normalized name: calcium acetate
DrugBank: Calcium Phosphate (DB11348)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
Trial: NCT00742820
Drug: Calcium Acetate 667 mg GelCaps
RxNorm normalized name: calcium acetate 667 MG
DrugBank: Calcium Phosphate (DB11348)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
Trial: NCT02811016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation at 7:00 a.m. and 7 p.m.
Trial: NCT00067990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with continued follow-up for five years.
Trial: NCT00002456
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04758728
Drug: Epinephrine Topical
RxNorm normalized name: EPINEPHrine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of epinephrine/adrenaline solution 1:1000 topically
Trial: NCT00727415
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
Trial: NCT00745771
Drug: Diractin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04198948
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
Trial: NCT02647788
Drug: Acetaminophen/Ibuprofen
RxNorm normalized name: ACETAMINOPHEN/IBUPROFEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
Trial: NCT02647788
Drug: Acetaminophen/Codeine
RxNorm normalized name: ACETAMINOPHEN/CODEINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
Trial: NCT00651313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal gel administered once daily for 4 days
Trial: NCT02290340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo intramuscularly.
Trial: NCT02290340
Drug: MEDI8897 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
Trial: NCT02290340
Drug: MEDI8897 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Trial: NCT04758728
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of normal saline solution NaCl 0,9% topically
Trial: NCT01795729
Drug: optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated